Sodium Phosphate, Monobasic
drug drugOn this page
Also known as E-339(I)E339INS NO.339(I)INS-339(I)Ionosol bIonosol mbIonosol tMonobasic sodium phosphateMonosodium phosphateanhydrousSodium acid phosphateSodium biphosphateSodium dihydrogen phosphateSodium orthophosphate monobasicSodium phosphate monobasicSodium phosphate monobasic (anhydrous)Sodium phosphatemonobasicmonobasic anhydrousmonohydrate
Summary
Sodium Phosphate, Monobasic (CHEMBL1368) is an approved small molecule; indicated across 2 conditions including urinary tract infection and constipation disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 2 conditions
- Clinical trials: 2
- Chemistry: H2O4P.Na
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1368 |
| Name | Sodium Phosphate, Monobasic |
| Type | Small molecule |
| Max phase | 4 |
| ChEBI | CHEBI:37585 |
| Molecular formula | H2O4P.Na |
| InChIKey | AJPJDKMHJJGVTQ-UHFFFAOYSA-M |
SMILES: O=P([O-])(O)O.[Na+]
Also known as: E-339(I), E339, INS NO.339(I), INS-339(I), Ionosol b, Ionosol mb, Ionosol t, Monobasic sodium phosphate, Monosodium phosphate, anhydrous, Sodium acid phosphate, Sodium biphosphate
Patent coverage: 121,963 distinct patent families (259,620 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| urinary tract infection | 4 | MONDO:0100338 | EFO:0003103 |
| constipation disorder | 4 | MONDO:0002203 | MONDO:0002203 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00493662 | PHASE4 | COMPLETED | Cross-Over Evaluation of Two Lubricating Eye Drops |
| NCT07233889 | Not specified | RECRUITING | Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: urinary tract infection, constipation disorder